Filing Flows › Gossamer Bio (GOSS) › Q2 2025
Gossamer Bio (GOSS) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 5, 2025
Gossamer Bio (GOSS) reported revenue of $11.5M for the second quarter 2025 (Q2 2025), -88% from a year earlier and +16% from the quarter before. Operating margin was -337.4%, net loss $38.3M (333.1% of revenue).
Gossamer Bio, Q2 2025: revenue $11.5M (-88% year over year), operating margin -337.4%, net loss $38.3M, operating cash flow −$47.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11.5M | +16% | -88% |
| Operating profit | −$38.8M | — | — |
| Net earnings | −$38.3M | — | — |
| Operating cash flow | −$47.1M | — | — |
What changed
Revenue was $11.5M in Q2 2025, down 88% year over year and up 16% from the previous quarter.
Operating costs exceeded revenue by $38.8M, an operating margin of -337.4%. Total costs grew 15% against a revenue fall of 88%. The fastest-growing cost line was Research & development (+18%). The quarter ended with a net loss of $38.3M, wider than the previous quarter's $36.6M loss.
Operating cash flow was −$47.1M. Non-cash charges added back $6K of depreciation and amortization and $2.6M of share-based compensation. Working capital and other items used $11.4M. Capital expenditures of $53K exceeded it, leaving free cash flow of −$47.1M.
Questions
What was Gossamer Bio's revenue in the second quarter 2025?
Gossamer Bio (GOSS) reported revenue of $11.5M for the second quarter 2025 (Q2 2025), -88% from a year earlier and +16% from the quarter before.
Was Gossamer Bio profitable in the second quarter 2025?
Operating loss was $38.8M (-337.4% of revenue) and net loss $38.3M.
Source: Gossamer Bio 10-Q on SEC EDGAR.